Have an eye on: T2 Biosystems, Inc. (NASDAQ:TTOO) declared Preliminary Fourth Quarter and Full Year 2020 Results

On 01-28-2k21 (Thursday) Shareholders tracking shares of T2 Biosystems, Inc. (TTOO) belongs to Healthcare sector and Diagnostics & Research industry. TTOO flaunted -20.28% to reach at $2.24 during previous trading session. TTOO Inc. has a total market value of 333.24M at the time of writing – representing $147.79M outstanding shares. Turning to other widely-considered trading data, th T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2020. is company’s half yearly performance is observed at 40.88%.

Financial and Operational Highlights

  • Preliminary unaudited fourth quarter 2020 total revenue is expected to be $7.8 million, including product revenue of $5.8 million, representing growth of 155% and 274% respectively, compared to the prior year period
  • Preliminary unaudited full year 2020 total revenue is expected to be $18.1 million, including product revenue of $11.7 million, representing growth of 118% and 119% respectively, compared to the prior year period
  • Sold 21 T2Dx® Instruments in the fourth quarter, including 19 in the U.S.
  • Sold 53 T2Dx Instruments in 2020, including 47 in the U.S., more than doubling the U.S. installed base in 2020
  • Achieved U.S. sepsis test utilization growth resulting in a fourth quarter annualized run rate of approximately $86,000 per legacy instrument and U.S. COVID test utilization growth resulting in a fourth quarter annualized run rate of approximately $265,000 per instrument sold in 2020
  • Unaudited cash, cash equivalents, current and long-term marketable securities, and restricted cash totaled $52.7 million as of December 31, 2020
  • In January 2021, the Company’s Term Loan Agreement with CRG was amended to extend the interest-only and principal payment periods to December 31, 2022, and to reduce the minimum product revenue target for the twenty-four month period beginning on January 1, 2020

“During 2020, our team made meaningful progress toward our three corporate priorities: accelerating our commercialization, improving our operations, and advancing our new product pipeline. Amid the global health emergency, we took rapid action to meet the COVID-19 testing needs of U.S. hospitals by developing and commercializing the T2SARS-CoV-2™ Panel. This has accelerated our business case and our business profile by allowing us to significantly increase our installed base of T2Dx Instruments in U.S. hospitals,” said John Sperzel, President and CEO of T2 Biosystems. “We saw increased adoption of our T2Dx Instruments in the second half of the year, showed meaningful improvement in the annualized test utilization of our sepsis and COVID test panels, and ended the year with a strong balance sheet. While the COVID testing needs of our customers will continue to fluctuate as we experienced in the fourth quarter, we are confident that we are entering 2021 in a stronger position, and are excited to drive continued adoption of our products and sustained growth through increased utilization of our highly-differentiated sepsis products.”

The Company’s fourth quarter and full year 2020 financial results are preliminary and are subject to the completion of the Company’s 2020 audit. Complete fourth quarter and full year 2020 financial results will be announced in early March.

Volume Evaluation

The USA listed company saw a recent price trade of $2.24 and 37,433,408 shares have traded hands in the session. There are 7.94M shares which are traded as an average over the last three months period.

Many investors forget that one of the defining characteristics of the stock market is that it’s a market. Buyers and sellers help determine the price of each stock, and the more buyers and sellers a particular stock has interested in it, the more liquid the market will be. Liquidity can have a profound impact on just how violently stock prices can move in either direction, and the reasons have to do with the nature of the market in a stock’s shares.

Trading volume, or volume, is the number of shares or contracts that indicates the overall activity of a security or market for a given period. Trading volume is an important technical indicator an investor uses to confirm a trend or trend reversal. Volume gives an investor an idea of the price action of a security and whether they should buy or sell the security.

Performance Levels

Looking performance record on shares of T2 Biosystems, Inc. (TTOO) we observed that the stock has seen a move 107.41% over the last 52-week trading period. The stock generated performance of 67.16% tracking last 3 months. Investors will be anxiously watching to see if things will turn around and the stock will start gaining or losing momentum over the next few months. If we look back year-to-date, the stock has performed 80.65%. Shares are at 19.79% over the previous week and 93.10% over the past month.

Analyst Views:

Fluctuating the focus to what the Wall Street analysts are projecting, we can see that the current consensus target price on shares is $3.22. Analysts often put in a lot of work to study stocks that they cover. Wall Street analysts have a consensus recommendation of 1.40on this stock. This number falls on a one to five scale where a 1 would be considered a strong buy and 5 means a strong sell, 2 shows Buy, 3 Hold, 4 reveals Sell recommendation.

Volatility Insights

Watching some historical volatility numbers on shares of T2 Biosystems, Inc. (TTOO) we can see that the 30 days volatility is presently 12.50%. The 7 days volatility is 18.94%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

The company has a beta of 0.68. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.

The Average True Range (ATR) value reported at 0.25. The average true range (ATR) is a technical analysis indicator that measures volatility by decomposing the entire range of an asset price for that period. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. The ATR may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. It was created to allow traders to more accurately measure the daily volatility of an asset by using simple calculations. The indicator does not indicate the price direction; rather it is used primarily to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.

Technical Considerations

T2 Biosystems, Inc. (TTOO) stock positioned 78.28% distance from the 200-day MA and stock price situated 66.99% away from the 50-day MA while located 35.59% off of the 20-day MA.

RSI value sited with reading of 54.55. Relative Strength Index (RSI) is an extremely useful and popular momentum oscillator. The RSI compares the magnitude of a stock’s recent gains to the magnitude of its recent losses and turns that information into a number that ranges from 0 to 100. It takes a single parameter, the number of time periods to use in the calculation. In his book, Wilder recommends using 14 periods.

Observing the Technical Indicators:

T2 Biosystems, Inc. institutional ownership is held at 12.70% while insider ownership was 0.10%. As of now, TTOO has a P/S, P/E and P/B values of 24.87, 0 and 18.67 respectively. Its P/Cash is valued at 8.11. The Company’s net profit margin for the 12 months at 0. Comparatively, the gazes have a Gross margin -25.40%.

Profitability ratios:

Looking into the profitability ratios of TTOO stock, an investor will find its ROE, ROA, ROI standing at 714.40%, -96.50% and -584.90%, respectively.

Earnings per Share Details of T2 Biosystems, Inc.:

The EPS of TTOO is strolling at -0.68, measuring its EPS growth this year at -2.80%. As a result, the company has an EPS growth of 0 for the approaching year.

Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.

Reynolds Smith

About Reynolds Smith

Myself Reynolds Smith and I am energetic about business and Healthcare & Biotech news with more than 11 years in the industry, beginning my venture as an author and later on climbing my way up into senior positions. I am the main stimulus behind Alphafinews.com started off with a dream to expand the organization’s reach out on a global scale. My writing style is diversifying, I write on a variety of topics but my personal favorite is lifestyle and business. I love communicating myself through artistic and innovative means such as writing, and painting. When I’m not doing any specific field related work, I enjoy spending some time with my dog, playing hockey or meeting my friends and family members. I never give up. I like French fries and Belgian waffles. I am an editor and contributor of the Health segment. I undergo critical analysis of corporations and extract the most significant information for our rich investor network.

View all posts by Reynolds Smith →